Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

New biosensor device may help in combating cancer

A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.

5 Nov 2009

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed rheumatologists indicate they will prescribe Roche's Actemra, an interleukin-6 inhibitor, for the treatment of rheumatoid arthritis following the agent's expected launch in 2010.

4 Nov 2009

MRF's research Consortium to develop effective treatments for advanced melanoma

For more than a decade, there have been no new therapies that have improved survival rates for patients with advanced melanoma. Today, at the 6th International Melanoma Congress for the Society for Melanoma Research, the Melanoma Research Foundation (MRF) announced a novel collaboration between the research community and pharmaceutical companies that will pool knowledge and resources to generate new breakthroughs in treatment.

4 Nov 2009

Helper T cell's effect raises possibility of cellular therapy and vaccine development

A specific type of T helper cell awakens the immune system to the stealthy threat of cancer and triggers an attack of killer T cells custom-made to destroy the tumors, scientists from The University of Texas M. D. Anderson Cancer Center report in the early online edition of the journal Immunity.

30 Oct 2009

Interleukin Genetics and Amway Global sign partnership agreement

Interleukin Genetics, Inc. announced today it has entered into an agreement with Amway Global. With this agreement, Amway Global Independent Business Owners will be able to sell Interleukin Genetics' Inherent Health(TM) brand of genetic tests, including the new Weight Management Genetic Test.

29 Oct 2009

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

Pregnant women with significant symptoms of depression tend to have a stronger biological reaction to the seasonal flu vaccine than do women with lower depression levels, according to a new study.

29 Oct 2009

TNF-alpha inhibitors and interleukin inhibitors to drive psoriasis drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive the psoriasis drug market to increase from $3 billion in 2008 to $5.2 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

27 Oct 2009

Sperm can transmit HIV to macrophages and dendritic cells

Sperm, and not just the fluid it bathes in, can transmit HIV to macrophages, T cells, and dendritic cells (DCs), report a team led by Ana Ceballos at the University of Buenos Aires in Argentina.

27 Oct 2009

Probiotic therapy can be effective for treating intestinal disorders

The probiotic, Bacillus polyfermenticus, can help mice recover from colitis, a new study has found. Mice treated with B. polyfermenticus during the non-inflammatory period of the disease had reduced rectal bleeding, their tissues were less inflamed and they gained more weight than mice that did not receive the treatment.

26 Oct 2009

New findings demonstrating pharmacoeconomic benefits of Ceplene released

EpiCept Corporation announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.

26 Oct 2009

Findings may lead to new vaccine strategies for pulmonary tularemia

Immunologists at the University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC and the have found a unique quirk in the way the immune system fends off bacteria called Francisella tularensis, which could lead to vaccines that are better able to prevent tularemia infection of the lungs. Their findings were published today in the early, online version of Immunity.

23 Oct 2009

Brain inflammation not linked to Alzheimer's disease

In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.

23 Oct 2009

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Genentech, Inc., a wholly-owned member of the Roche Group, today announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent).

19 Oct 2009

IL-2 compound ineffective against HIV-AIDS

An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped.

19 Oct 2009

Breakthrough discovery by scientists may lead to a new treatment for Alzheimer's Disease

A breakthrough discovery by scientists from the Mayo Clinic in Jacksonville, FL, may lead to a new treatment for Alzheimer's Disease that actually removes amyloid plaques-considered a hallmark of the disease-from patients' brains.

19 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it will present new genetic findings in the fields of obesity and osteoporosis at medical meetings later this month.

13 Oct 2009

Inflammation markers not involved with the chemopreventative effect of aspirin on colorectal adenomas

Unexpectedly, inflammation markers do not appear to be involved with the chemopreventative effect of aspirin on colorectal adenomas, according to a brief communication published online October 12 in the Journal of the National Cancer Institute.

13 Oct 2009

Depression leads to elevated inflammatory proteins in the human body: Study

To help solve this long standing chicken and egg conundrum, researchers led by Jesse Stewart, Ph.D., assistant professor of psychology at Indiana University-Purdue University Indianapolis asked two critical questions. Does depression lead to elevated inflammatory proteins in the human body? Or does an increase in these proteins lead to depression? They found that the answer to the first question appears to be "yes," and the answer to the second question may be "no" among healthy adults.

6 Oct 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009

Interleukin 6 News and Research

Further Reading

New biosensor device may help in combating cancer

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

MRF's research Consortium to develop effective treatments for advanced melanoma

Helper T cell's effect raises possibility of cellular therapy and vaccine development

Interleukin Genetics and Amway Global sign partnership agreement

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

TNF-alpha inhibitors and interleukin inhibitors to drive psoriasis drug market

Sperm can transmit HIV to macrophages and dendritic cells

Probiotic therapy can be effective for treating intestinal disorders

New findings demonstrating pharmacoeconomic benefits of Ceplene released

Findings may lead to new vaccine strategies for pulmonary tularemia

Brain inflammation not linked to Alzheimer's disease

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

IL-2 compound ineffective against HIV-AIDS

Breakthrough discovery by scientists may lead to a new treatment for Alzheimer's Disease

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Inflammation markers not involved with the chemopreventative effect of aspirin on colorectal adenomas

Depression leads to elevated inflammatory proteins in the human body: Study

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News